Certara, Inc. (CERT)
After hours: 04:05PM EDT
| Previous Close | 37.75 |
| Open | 37.38 |
| Bid | 37.50 x 1000 |
| Ask | 39.00 x 800 |
| Day's Range | 36.79 - 38.50 |
| 52 Week Range | 23.75 - 41.79 |
| Volume | 469,070 |
| Avg. Volume | 917,207 |
| Market Cap | 5.955B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.39 |
| Earnings Date | Aug. 05, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.75 |
- GlobeNewswire
Certara Appoints Patrick F. Smith to President of Integrated Drug Development
PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrated Drug Development (IDD), reporting to CEO William F. Feehery. Dr. Smith will lead the Company’s global drug development services team, which creates value for clients across the entire drug development life cycle using biosimulation and quantitative approaches. Dr. Smith succeeds Craig R. Rayner,
- GlobeNewswire
Certara Appoints Drayton T. Virkler as Chief Commercial Officer
Experienced commercial leader brings 20 years of experience in pharmaPRINCETON, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer. In this role, Mr. Virkler will drive the Company’s global commercial strategy and execution and expand the business development team. “I am pleased to welcome Drayton as our new Chief Commercial Officer,
- GlobeNewswire
Certara Completes Acquisition of Pinnacle 21
Complementary technologies accelerate and help assure success in the drug development processPRINCETON, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness. At closing, equity holders of Pinnacle 21 received approximately $250 million in cash
